

Special Issue

Cancer Associated Coagulation

Message from the Guest Editor

This Special Issue aims to encompass research in all aspects of cancer-associated coagulation, from understanding the mechanisms of tumour-driven hypercoagulopathy to advances in anticoagulant treatment and patient management. Certain tumours, such as those of the pancreas and ovaries, are associated with an increased risk of the patient developing venous thromboembolism and this risk increases further with chemotherapy by mechanisms currently being investigated. Patients are managed with the use of anticoagulants such as low-molecular-weight heparin or orally administered alternatives. Of particular interest is the role of extracellular vesicles within these processes, although studies on all aspects of cancer-associated coagulation are welcome.

Guest Editor

Dr. Leigh A. Madden

Department of Biomedical Science, The University of Hull, Hull HU6 7RX, UK

Deadline for manuscript submissions

closed (1 March 2025)



Hemato

an Open Access Journal
by MDPI

Impact Factor 1.0
CiteScore 2.0



mdpi.com/si/64191

Hemato
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
hemato@mdpi.com

mdpi.com/journal/

hemato





Hemato

an Open Access Journal
by MDPI

Impact Factor 1.0
CiteScore 2.0



[mdpi.com/journal/
hemato](https://mdpi.com/journal/hemato)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Antonino Carbone

Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a
Carattere Scientifico, 33081 Aviano, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 33.8 days after
submission; acceptance to publication is undertaken in 2.5
days (median values for papers published in this journal in
the first half of 2025).